Lasting high? Cannabis industry aims to build on Thanksgiving rush
Send a link to a friend
[December 07, 2020] By
Shariq Khan
(Reuters) - U.S. cannabis sales hit record
levels over the Thanksgiving weekend, prompting industry predictions the
combination of COVID-19 anxiety and a trend towards legalisation has
triggered a permanent uplift in demand.
After years of sluggish official sales, buying soared in early March and
April when lockdowns began and consumers, fearing supply disruptions,
stockpiled the drug.
Though many expected the initial surge to fade, monthly sales have kept
hitting records.
One of the top cannabis data aggregator and research companies Akerna
KERN.O said sales on Green Wednesday, as the eve of Thanksgiving is
known, climbed by 80% above the daily average this year, hitting an
all-time one-day record.
The company's calculations, based on data collected from its partner
dispensaries in 19 U.S. states and adjusted to project the full market,
show total cannabis sales of around $238 million during the Thanksgiving
weekend, nearly 14% above last year.
By keeping people at home, limiting their entertainment options and
adding to stress, the pandemic has helped to drive demand for cannabis
for much of the year.
Four in 10 users increased their overall consumption and more than half
said they turned to cannabis to improve mental health, an advance copy
of a report by research firm New Frontier Data, which is to be published
next week, showed.
'COME TO JESUS' MOMENT
Even if COVID-19 vaccines can bring back a degree of normality, insiders
and observers say 2020 is likely to mark a watershed for the cannabis
industry, as for many other sectors.
"The shutdowns created a real 'come to Jesus' moment for a lot of
stakeholders," Avis Bulbulyan, Chief Executive of cannabis consultancy
Siva Enterprises, said. "Consumer acceptance went through the roof."
As a result, operators upgraded their plans and attracted mainstream
investors that before showed little interest in the nascent industry.
Further legitimacy came from the decision of state regulators to
designate cannabis retailers as "essential business" during lockdowns,
and, in the U.S. elections on Nov. 3, initiatives to legalise
recreational or medical marijuana, which five states put on the ballot,
sailed through.
The House of Representatives on Friday passed a bill to end federal
prohibition, though the chances of it progressing further are seen as
slim, with Republican Senate majority leader Mitch McConnell leading
opposition to it becoming law.
Graphic: Big Wins for Marijuana Ballots - https://graphics.reuters.com/USA-CANNABIS/gjnvwbmndpw/chart.png
At a local level, thirty-five states allow medical marijuana use, some
with restrictions, and 15 states, plus the District of Columbia, have
legalised its recreational use.
Opposition persists, however, with some groups saying it causes
addiction and that not enough research has been carried out to prove
medical benefits.
The states of Idaho and Nebraska have bans in force. Activists in favour
of cannabis are seeking a vote to try to overturn them in 2022 mid-term
elections.
Stuart Titus, an early cannabis investor and CEO of Medical Marijuana
Inc MJNA.PK, says 2021 could be the year when cannabis becomes as
readily available as alcohol and tobacco.
[to top of second column] |
Customers are given hand sanitizer before being allowed to enter The
Reef Cannabis shop, amid the coronavirus disease (COVID-19)
outbreak, in Seattle, Washington, U.S., March 20, 2020.
REUTERS/Brian Snyder/File Photo
"Shortly in restaurants, consumers will have the choice of an alcoholic beverage
or a cannabis-based beverage," he said.
Graphic: States that have legalized marijuana in the United States - https://graphics.reuters.com/USA-CANNABIS/jznvnnwwqvl/chart.png
FEDERAL VERSUS STATE
Marijuana remains illegal under federal law, which has limited the industry's
access to banking services and funding.
Vice President-elect Kamala Harris' has promised to change that and
decriminalising weed is part of the Democrats' platform.
Industry insiders acknowledge it may take years for any changes to make their
way through the legislative process, but shifts in sentiment are moving more
quickly.
A Gallup poll in November showed support for marijuana legalisation had reached
68% support, the highest level yet and up from 66% last year.
At the same time, a separate Gallup poll found 70% of U.S. adults consider
smoking marijuana to be "morally acceptable," a 5 point rise in a year.
Solid majorities for legalisation in traditionally conservative states, such as
North and South Dakota or Missouri, could also help to win over Republican
lawmakers and local politicians, Steve Allan, chief executive of Californian
producer The Parent Company, said.
"With many Republican Senators now representing states that have passed cannabis
legalisation measures by wide margins, we will likely see increased support from
Republicans for federal cannabis reforms," he said.
Akerna CEO Jessica Billingsley said her company has received a record number of
research requests from state governments, which have lost tax revenues to
business closures during the pandemic and are looking for new sources of income.
"Lawmakers see cannabis legalisation as a great way to shore up their balance
sheets and provide jobs during this time of economic uncertainty," she told
Reuters.
The experience in Canada could yet serve as a cautionary tale.
It became the first major nation to legalise recreational weed in 2018, but
industry hopes were dashed by oversupply, black markets and lack of
profitability.
Producers and research firms say the United States is better placed to succeed
because of the vast size of the potential market, new products and greater
awareness of the therapeutic benefits of cannabis.
"What used to be a 'recreational drug' is being better understood to be a
complex compound with a long list of potential benefits for both the mind and
body," The Parent Company's Allan said.
(Reporting by Shariq Khan in Bengaluru; Editing by Tomasz Janowski and Barbara
Lewis)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |